First‐line immune‐based combination therapies for advanced non‐small cell lung cancer: A Bayesian network meta‐analysis-Reference-Cited by-同舟云学术

First‐line immune‐based combination therapies for advanced non‐small cell lung cancer: A Bayesian network meta‐analysis

Author:

Mao Ziyang¹,Jiang Panpan¹,Zhang Yajuan¹,Li Yanlin¹,Jia Xiaohui¹,Wang Qinyang¹,Jiao Min¹,Jiang Lili¹,Shen Yuan²,Guo Hui¹³⁴^ORCID

Affiliation:

1. Department of Medical Oncology The First Affiliated Hospital of Xi’an Jiaotong University Xi’an Shaanxi P.R. China

2. Department of Epidemiology and Biostatistics School of Public Health Xi'an Jiaotong University Health Science Center Xi’an Shaanxi P.R. China

3. Key Laboratory of Environment and Genes Related to Diseases Xi'an Jiaotong UniversityMinistry of Education of China Xi'an Shaanxi P.R. China

4. Centre for Translational Medicine The First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi P.R. China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

Reference52 articles.

2. Global epidemiology of lung cancer;Barta JA;Ann Glob Health,2019

5. Combination therapy with PD‐1/PD‐L1 blockade in non‐small cell lung cancer: strategies and mechanisms;Huang MY;Pharmacol Ther,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献